Celgene Corporation and bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene-therapy company, have agreed to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy, for the potential treatment of patients with relapsed/refractory multiple myeloma in the US.

The companies originally entered into a broad, global research collaboration in 2013 to discover, develop, and commercialize therapies in oncology, which included bb2121.

For bb2121, bluebird and Celgene have joint responsibility for development, manufacturing, and commercialization in the US. Celgene will assume sole responsibility for drug-product manufacturing and commercialization outside the US. bluebird bio and Celgene are also working together on a second clinical-stage anti-BCMA CAR-T program, bb21217.

Source: Celgene and bluebird bio